Real world data of short-term efficacy of Budesonide enteric-coated capsules in treating primary IgA nephropathy from a single center

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/efc2ae0f0c7474585248e8bb4e96c661.pdf

Abstract Title *

Real world data of short-term efficacy of Budesonide enteric-coated capsules in treating primary IgA nephropathy from a single center

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Shaomin GONG gong.shaomin@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China * Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 2

Yichun NING ning.yichun@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 3

Ziyan SHEN shen.ziyan@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 4

Shi JIN jin.shi@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 5

Hong LIU liu.hong@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 6

Yiqin SHI shi.yiqin@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 7

Xiaoqiang DING ding.xiaoqiang@zs-hospital.sh.cn Zhongshan Hospital, Fudan University Department of Nephrology Shanghai China - Shanghai Medical Center of Kidney Disease Department of Nephrology Shanghai China Shanghai Institute of Kidney and Dialysis Department of Nephrology Shanghai China

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

The early efficacy of budesonide enteric-coated capsules in treating primary IgA nephropathy remains to be studied, which holds vital guiding significance to optimize treatment.

Methods

Patients with primary IgA nephropathy treated with budesonide enteric-coated capsules at Zhongshan Hospital, Fudan University from January 2025 to June 2025 were analyzed. Budesonide enteric-coated capsules were prescribed according to the clinical situation without any interventions. Changes in urinary proteinuria quantitation and renal function were assessed in duration of 24-weeks treatment.

Results

A total of 144 patients with primary IgA nephropathy were included, with a mean age of 43.09±11.56 years, including 80 males (55.56%). Urinary total protein (UTP) was 1.94±1.9 g/d before treatment, urinary red blood cell count was 241.64±69/uL with 13 patients had a history of gross hematuria. The baseline estimated glomerular filtration rate (eGFR) was 56.72±29.65 mL/min/1.73m². Sixty patients had received glucocorticoids concomitantly and six had immunosuppressants other than glucocorticoids. By the 8th week of treatment, UTP decreased by 13.19% compared to baseline (P=0.029). UTP sustained to decrease by 36.29% by the 24th week (P<0.001). As to the renal function, the eGFR increased by 5.23% compared to baseline by the 8th week (P=0.105) and finally increased by 9.79% at 24th week with an upward trend (P=0.171).

Conclusion

Budesonide enteric-coated capsules demonstrated an early significant reduction in proteinuria with mild increased eGFR at the 8th week of treatment in primary IgA nephropathy. The early efficacy remained significant till the 24th weeks, suggesting the effectiveness in short-term treatment.

Kewords